Nakamura Satoko, Kawano Yuhei, Hase Hiroki, Hatta Tsuguru, Nishimura Shigeyuki, Moroi Masao, Nakagawa Susumu, Kasai Tokuo, Kusuoka Hideo, Takeishi Yasuchika, Nakajima Kenichi, Momose Mitsuru, Takehana Kazuya, Nanasato Mamoru, Yoda Syunichi, Nishina Hidetaka, Matsumoto Naoya, Nishimura Tsunehiko
Department of Medicine, Division of Hypertension and Nephrology, National Cardiovascular Center, Suita, Japan.
Ther Apher Dial. 2010 Aug 1;14(4):379-85. doi: 10.1111/j.1744-9987.2010.00823.x.
Cardiovascular disease is the leading cause of morbidity and mortality in patients with chronic kidney disease. Recent studies have indicated that the incidence of cardiovascular disease increases inversely with estimated glomerular filtration rate. Although coronary angiography is considered the gold standard for detecting coronary artery disease, contrast-induced nephropathy or cholesterol microembolization remain serious problems; therefore, a method of detecting coronary artery disease without renal deterioration is desirable. From this viewpoint, stress myocardial perfusion single photon emission computed tomography (SPECT) might be useful for patients with chronic kidney disease. We recently performed the Japanese Assessment of Cardiac Events and Survival Study by Quantitative Gated SPECT (J-ACCESS) investigating patients with suspected or extant coronary artery disease and the J-ACCESS 2 study of patients with diabetes. The findings from these studies showed that SPECT can detect coronary artery disease and help to predict future cardiac events. Thus, we proposed a multicenter, prospective cohort study called "J-ACCESS 3" in patients with chronic kidney disease and cardiovascular risk. The study aimed at predicting cardiovascular and renal events based on myocardial perfusion imaging and clinical backgrounds. We began enrolling patients in J-ACCESS 3 at 74 facilities from April 2009 and will continue to do so until 31 March 2010, with the aim of having a cohort of 800 patients. These will be followed up for three years. The primary endpoints will be cardiac death and sudden death. The secondary endpoints will comprise any cardiovascular or renal events. This study will be completed in 2013. Here, we describe the design of the J-ACCESS 3 study.
心血管疾病是慢性肾脏病患者发病和死亡的主要原因。最近的研究表明,心血管疾病的发病率与估计肾小球滤过率呈负相关。尽管冠状动脉造影被认为是检测冠状动脉疾病的金标准,但造影剂肾病或胆固醇微栓塞仍然是严重问题;因此,需要一种在不导致肾脏恶化的情况下检测冠状动脉疾病的方法。从这个角度来看,负荷心肌灌注单光子发射计算机断层扫描(SPECT)可能对慢性肾脏病患者有用。我们最近开展了日本定量门控SPECT心脏事件与生存评估研究(J-ACCESS),调查疑似或已确诊冠状动脉疾病的患者,并开展了针对糖尿病患者的J-ACCESS 2研究。这些研究的结果表明,SPECT能够检测冠状动脉疾病并有助于预测未来心脏事件。因此,我们针对患有慢性肾脏病且有心血管风险的患者提出了一项名为“J-ACCESS 3”的多中心前瞻性队列研究。该研究旨在基于心肌灌注成像和临床背景预测心血管和肾脏事件。我们于2009年4月开始在74个机构招募J-ACCESS 3研究的患者,并将持续招募至2010年3月31日,目标是建立一个由800名患者组成的队列。这些患者将接受为期三年的随访。主要终点将是心源性死亡和猝死。次要终点将包括任何心血管或肾脏事件。这项研究将于2013年完成。在此,我们描述J-ACCESS 3研究的设计。